In the last trading session, 1.36 million Xeris Biopharma Holdings Inc (NASDAQ:XERS) shares changed hands as the company’s beta touched 1.77. With the company’s per share price at $1.89 changed hands at $0.0 or 0.26% during last session, the market valuation stood at $280.93M. XERS’s last price was a discount, traded about -72.49% off its 52-week high of $3.26. The share price had its 52-week low at $1.46, which suggests the last value was 22.75% up since then. When we look at Xeris Biopharma Holdings Inc’s average trading volume, we note the 3-month average coming to 1.86 million.
Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information
Instantly XERS was in green as seen at the end of in last trading. With action 8.29%, the performance over the past five days has been green. The jump to weekly highs of 1.9700 added 0.26% to the stock’s daily price. The company’s shares are showing year-to-date downside of -19.36%, with the 5-day performance at 8.29% in the green. However, in the 30-day time frame, Xeris Biopharma Holdings Inc (NASDAQ:XERS) is -7.11% down.
Xeris Biopharma Holdings Inc (XERS) estimates and forecasts
Data shows that the Xeris Biopharma Holdings Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 4.70% over the past 6 months, a 15.56% in annual growth rate that is considerably higher than the industry average of 11.70%. Year-over-year growth is forecast to reach 12.50% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 41.81M. 6 analysts are of the opinion that Xeris Biopharma Holdings Inc’s revenue for the current quarter will be 45.1M. The company’s revenue for the corresponding quarters a year ago was 33.2M and 38.01M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 25.90%. The estimates for the next quarter sales put growth at 18.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 38.13%. The 2024 estimates are for Xeris Biopharma Holdings Inc earnings to increase by 23.17%.
